CIAM
FBRX

Caitong International Asset Management’s Forte Biosciences FBRX Stock Holding History

Caitong International Asset Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4K Buy
+113
New +$2.68K ﹤0.01% 1378

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Caitong International Asset Management's FBRX Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Forte Biosciences (FBRX) in Q2 2026: 113 shares worth $2.4K. The stake represents ﹤0.01% of the portfolio and ranks #1378 among its holdings.

86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Caitong International Asset Management held 113 shares of Forte Biosciences worth $2.4K as of Q2 2026.
  • Forte Biosciences was a new Caitong International Asset Management position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1378 holding.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.